-

QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025.

Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, February 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.

Three options for joining the conference call

Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts

Dial-in by phone
U.S.: +1 646 769 9200
UK: +44 (0)20 7769 6464
GER: +49 (0)69 254 99300
Conference ID: 3382302
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Access the audio webcast - Click here: Access Webcast

A conference call replay will be available by using the following link:
https://event.webcasts.com/starthere.jsp?ei=1730547&tp_key=61217c6183

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of September 30, 2025, QIAGEN employed approximately 5,700 people across over 35 locations. For more information, visit https://www.qiagen.com.

Source: QIAGEN N.V.

category: Financial

Contacts

Daniel Wendorff, CIIA
Vice President Head of Investor Relations
+49 2103 29 11322
+49 152 018 11322
Email: ir@qiagen.com

Dr. Domenica Martorana
Associate Director Investor Relations
+49 2103 29 11244
+49 152 018 11244
Email: ir@qiagen.com

QIAGEN N.V.

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)

Release Versions

Contacts

Daniel Wendorff, CIIA
Vice President Head of Investor Relations
+49 2103 29 11322
+49 152 018 11322
Email: ir@qiagen.com

Dr. Domenica Martorana
Associate Director Investor Relations
+49 2103 29 11244
+49 152 018 11244
Email: ir@qiagen.com

More News From QIAGEN N.V.

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined QIAGEN as Chief Executive Officer on September 1, 2026. Subject to shareholder approval, Jon Pratt would join Roland Sackers, Chief Financial Officer, as the two me...

QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and...

QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corpor...
Back to Newsroom